A trial to study the efficacy and safety of TERT mRNA survivin peptide loaded dendritic cell vaccine in patients with advanced ovarian cancer

Trial Profile

A trial to study the efficacy and safety of TERT mRNA survivin peptide loaded dendritic cell vaccine in patients with advanced ovarian cancer

Planning
Phase of Trial: Phase II

Latest Information Update: 12 Apr 2016

At a glance

  • Drugs TERT mRNA-survivin peptide-loaded dendritic cell vaccine (Primary) ; Bevacizumab; Carboplatin; Gemcitabine
  • Indications Ovarian cancer
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 12 Apr 2016 Trial has been created from the information available on the company website (http://www.cellmed.eu/)
    • 12 Apr 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top